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Male LUTS – Introduction and
Overview
Thenappan Chandrasekar, MD
Urologic Oncology & Urology
TJU Center City & Abington

Outline & Goals
• Background – What are “LUTS”?
• Anatomy
• Pathophysiology
• Storage – bladder filling symptoms
• Voiding – urine flow symptoms
• Post-micturition

• Major etiologies and management
• BPH / BOO
• OAB
• Nocturia

• Related to Prostate Cancer?

What are “LUTS”
• Non-specific!
• Any combination of urinary symptoms or
• Symptoms primarily associated with overactive bladder
(frequency, urgency, and nocturia)
• International Consensus Conference (2005) defined LUTS to
include symptoms relating to storage and/or voiding
disturbances common among aging men
• So, the more detail you get, the better you can identify the
problem!

Epidemiology

Rancho Bernardo study – prospective administration of AUA Symptom Index (0-35 points)
•

60% of the entire cohort had LUTS – but increased significantly with each decade age

Parson JK et al. Urology 2008.

Aging Population
• The number of
Americans ages 65 and
older will more than
double over the next
40 years, reaching 80
million in 2040.
• The number of adults
ages 85 and older, the
group most often
needing help with
basic personal care,
will nearly quadruple
between 2000 and
2040.

Aging Population

MALE GENITOURINARY ANATOMY

ANATOMY
Sphincter mechanism

ANATOMY

Pathophysiology of LUTS

Pathophysiology of LUTS

Etiologies of LUTS

BPH & BOO
First, we need to define these terms:
• Benign Prostatic Hyperplasia (BPH)
• Histologic diagnosis
• stromoglandular hyperplasia

• Benign prostatic enlargement (BPE)
• Anatomic enlargement of the gland

• Bladder Outlet Obstruction (BOO)
• Actual manifestation of symptoms
• Pathophysiologic
• Obstruction of the urethra &
compromise of urinary flow

BPH-Mass Effect
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BPE & BOO
• Size doesn’t always matter!

The size of the gland does not necessarily predict symptom severity. Some
men with minimally enlarged prostate glands experience many symptoms
while other men with much larger glands have few symptoms.

What Are the Symptoms of BPH?

What Are the Symptoms of BPH?

BPH – Long-term Complications
• Silent BPH
•
•
•
•
•
•

Urinary retention
UTI
Bladder stones
Bladder decompensation
Renal insufficiency
Hematuria

Bladder Changes from BPH
• Detrusor instability
• Decreased compliance
(frequency and urgency)
• Impaired detrusor contractility
• Trabeculation (increase in
detrusor collagen)
• Diverticulum

AUA Symptom Score Index
Seven questions (0-5):
• Incomplete
emptying
• Frequency
• Hesitancy
• Urgency
• Weak stream
• Strained voiding
• Nocturia

AUA Symptom Score Index
Mild
Moderate
Severe

0-7
8-19
20-35

* Moderate to severe symptoms are 3.5X higher in men with
>50 ml prostate

BPH – Diagnosis & Evaluation
• Detailed history (hematuria, UTI, Diabetes, Neurolgic
Disease, h/o urethral strictures, urinary retention,
aggravation of symptoms with cold meds)
• Physical Exam: DRE and focused neurologic exam
• AUA Symptom Score Index
• U/A
• ? Serum Creatinine
• PSA

Diagnosis-Additional Tests
Urinary flow rate
Post-void residual (Bladder scan)
Pressure-Flow studies
Urethrocystoscopy - indicated for planned invasive therapy,
hematuria, strict disease, previous surgery
• Radiologic imaging – Transrectal / Transabdominal U/S or IVU
•
•
•
•

BPH - Treatment
• In 1990 - 335,000 surgical procedures for BPH
• TURP was the most common procedure

• Medical therapy and minimally invasive techniques have
decrease the number of surgical intervention
• 25% of men by age of 80 will undergo treatment
• Cost issue

BPH - Treatment
• Watchful waiting
• Medical Therapy
• Minimally Invasive Techniques- Prostatic Urethral Lifts
and Steam Thermotherapy
• Surgical Therapy

BPH – Treatment Trends

BPH Treatment - ”Watchful Waiting
Advantages
• No surgery
• No drugs
• No side effects

Disadvantages
• No improvement in symptoms
• Risk that symptoms or
obstruction will worsen

BPH - Medical Therapy
•
•
•
•
•

First line of treatment for LUTS secondary to BPH
Alpha blockers
Low dose Tadalafil (Cialis)
Androgen Suppression
Phytotherapy

Medical Therapy - Alpha Blockers
• Non selective Phenoxybenzamine, alfuzosin (IR),Indoramin
• Long acting- terazosin, doxasosin, alfuzosin SR, Silodosin
• Subtype selective- tamsulosin

Medical Therapy - Distribution of alpha-receptors

Medical Therapy - Alpha blockers
• Multicenter, randomized, double-blind, placebo controlled
studies have demonstrated safety and efficacy
• Rapid and dose dependent
• Durable

Medical Therapy - Androgen Suppression
• GnRH Analogs- Leuprolide, Nafarelin, Cetrorelix
• Progestational Agents-Megestrol, 17 alpha-Hydrocortisone
• Antiandrogens-flutamide, biculatamide, oxandolone,
zanoterone
• 5 alpha reductase inhibitors (5ARIs)
• Finasteride (Proscar)
• Dutasteride (Avodart)

Medical Therapy – 5ARI’s
•
•
•
•

Safety and efficacy has been established
Durable
Reduces prostate size by 20%
? Preventive for prostate cancer

Treatment Option – Medical Management
Advantages
• No surgery
• Potential for full symptom
resolution

Disadvantages
• Lifelong commitment
• Side effects
• Effectiveness of drugs lessens over
time
• Ongoing out-of-pocket costs

BOO 2/2 BPH – Surgical Treatment

Office Based - Minimally Invasive Therapies
(MIT)
■ Prostatic Urethral Lift – UroLift

■ Steam Thermotherapy - Rezum

Operating Room - Minimally Invasive
Treatment Options
• Laser - TULIP, VLAP,
contact laser
• Laser - Holmium Laser
Prostatectomy (HoLEP) à

• TURP

Surgical Therapy
• TURP - Holmium Laser
Prostatectomy (as discussed)
• Open Prostatectomy ààà
• Minimally Invasive Techniques
(Robotic) à

BPH - Surgical Therapy – Take Home Points
• TURP is still considered gold standard
• Open/Robotic Prostatectomy is indicated in patients where
prostate glands are greater than 75-80 grams
• Holmium Laser Prostatectomy is an alternative to TURP
• No size limit in the AUA guidelines
• Only MIT that has no size limit

Treatment Option- Surgery
Advantages
• Proven approach
• Durable response
• Can allow patients to be off
medications

Disadvantages
• Requires hospitalization
• Requires general anesthesia
• Side effects can be significant

Surgical Indications
•
•
•
•
•
•

Recurrent UTI s
Gross Hematuria
Bladder calculi
Renal insufficiency
Urinary Retention
Bladder Diverticulum

BOO – Causes other than BPH
•
•
•
•
•
•

Urethral Strictures
Primary bladder neck obstruction
Bladder neck contracture
Detrusor-sphincter dyssynergia
Prostate cancer – late stage prostate cancer
Meatal stenosis (circumcised men)

Overactive Bladder (OAB)
• Definition: “urinary urgency, with or without urgency urinary
incontinence (involuntary loss of urine), in the absence of
urinary tract infection or other obvious pathology.”
• It is a clinical diagnosis
• Characterized by STORAGE symptoms – and ideally absence
of VOIDING/obstruction symptom

OAB - Epidemiology
Women > Men
But…
Still a problem in men!

Overactive Bladder (OAB) - Presentation

Overactive Bladder
(OAB) – Evaluation
• History (detailed)
• Neurogenic bladder
• Pelvic floor dysfxn
• UTI’s recurrent
• BOO
• Bladder Ca
(hematuria)
• Physical exam
• Urinalysis/Ucx (if
indicated)
• Postvoid residual (PVR)
• Symptom questionnaire
/ bladder diary

Overactive Bladder (OAB) – Secondary to BOO

Overactive Bladder (OAB) – Treatment Paradigm

Overactive Bladder (OAB) – Treatment Paradigm

OAB Treatment - Pathophysiology
Anticholinergics
• Block parasympathetic
innervation of detrusor
muscle
Beta-3 Agonist
• Activates relaxation of
detrusor smooth muscle

Overactive Bladder (OAB) – Medical Management

Overactive Bladder (OAB) – Anticholinergics

Overactive Bladder (OAB) – Beta-3 agonist

OAB Medication
Summary
• Clinicians should offer oral
antimuscarinics or oral β3adrenoceptor
• ER preferred over IR
• If one anti-muscarinic
ineffective, then dose
modification, different
anti-muscarinic or a β3agonist
• Can combine modalities
for pts refractory to
monotherapy

Overactive Bladder (OAB) – Surgical Treatments

Nocturia
• Definition: defined as the need to awaken ≥1 times per night
to void
• Why talk about this separately?
• Long been considered one of a range of symptoms associated
with LUTS – including BOO and OAB.
• Although nocturia is urinary frequency that occurs during
nighttime sleep, it is not necessarily driven by a lower urinary
tract dysfunction
• It may be driven instead by nighttime urine overproduction, or
nocturnal polyuria (NP), resulting from renal, cardiovascular, or
pulmonary factors

Nocturia – Non-Urologic Causes

Nocturia – Obstructive
Sleep Apnea

Nocturia – Conservative Treatment Rec’s

Nocturia – Medical Management
FIRST LINE THERAPY - Anticholinergic medication
If this first line drug therapy is considered ineffective, one or more of the following
may be prescribed:
1) Desmopressin - By mimicking ADH or vasopressin, the kidney produces less urine.
2) Imipramine - This medication boasts a 40% success rate but also has a fine line
between an effective dose and toxic dose.
3) Furosemide - This loop diuretic helps regulate urine production in the daytime in
order to decrease urine production during sleep. Furosemide blocks ion flow in
the kidneys, allowing urine production to be more controlled.
4) Bumetanide - This loop diuretic assists in regulating urine production prior to
sleep so waking during the nighttime does not occur. Bumetanide must be taken
with caution and consultation with a healthcare professional prior to taking this
medication is highly recommended.

Nocturia –
Medical
Management

How does this relate to Prostate Cancer?

Prostate Anatomy
• Prostate Cancer and
BPH occur in
different regions of
the prostate
• PCa rarely causes
urinary symptoms…
unless it is quite
advanced.

PSA

